https://www.selleckchem.com/pr....oducts/i-bet-762.htm
two doses of MenACWY-D. Adjuvanted NmCV-5 provided no discernible benefit over nonadjuvanted NmCV-5. (Funded by the U.K. Foreign, Commonwealth, and Development Office; ClinicalTrials.gov number, NCT03295318.). The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery to receive, in a 11 ratio, either nivolumab (
Like
Comment
Share
